Systemic lupus erythematosus and herpes zoster: Difficulties of curation (description of clinical observations)
Open Access
- 1 November 2024
- journal article
- Published by Mediar Press in Rheumatology Science and Practice
- Vol. 62 (5) , 564-569
Abstract
Patients with systemic lupus erythematosus (SLE) have an increased risk of developing herpes zoster (HZ). Vaccination difficulties arise in these patients due to possible interactions with the therapy used with glucocorticoids, disease-modifying antirheumatic drugs and biologic disease-modifying anti-rheumatic drugs. The description of two clinical observations of patients with SLE, who developed severe HZ against the background of active SLE and therapy with immunosuppressive drugs, is given. The issue of the need for vaccination in Russia against varicella zoster virus of patients on immunosuppressive therapy is discussed.Keywords
This publication has 20 references indexed in Scilit:
- 2022 American College of Rheumatology Guideline for Vaccinations in Patients With Rheumatic and Musculoskeletal DiseasesArthritis & Rheumatology, 2023
- Diagnostik, Therapie und Prophylaxe des Herpes zosterZeitschrift für Rheumatologie, 2020
- Trial of Anifrolumab in Active Systemic Lupus ErythematosusNew England Journal of Medicine, 2020
- Type I interferon inhibitor anifrolumab in active systemic lupus erythematosus (TULIP-1): a randomised, controlled, phase 3 trialThe Lancet Rheumatology, 2019
- Immunogenicity and safety of the adjuvanted recombinant zoster vaccine in adults with haematological malignancies: a phase 3, randomised, clinical trial and post-hoc efficacy analysisThe Lancet Infectious Diseases, 2019
- Mortality in systemic lupus erythematosus: causes, predictors and interventionsExpert Review of Clinical Immunology, 2018
- Herpes zoster vaccination in systemic lupus erythematosus: the current statusHuman Vaccines & Immunotherapeutics, 2018
- Risk Factors for Herpes Zoster: A Systematic Review and Meta-analysisMayo Clinic Proceedings, 2017
- Risk of Herpes Zoster in Autoimmune and Inflammatory Diseases: Implications for VaccinationArthritis & Rheumatology, 2016
- Efficacy and safety of rituximab in moderately‐to‐severely active systemic lupus erythematosus: The randomized, double‐blind, phase ii/iii systemic lupus erythematosus evaluation of rituximab trialArthritis & Rheumatism, 2009